Clinical trial
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and…
NCT00418626 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00418626 |
|---|---|
| Title | Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function |
| Official title | A Phase I, Single Center, Open-label, Single Oral Dose, Study to Assess the Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 27 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2007 |
| First posted | Jan 5, 2007 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: